Active Ingredient: Lenvatinib
Lenvatinib as monotherapy is indicated for the treatment of adult patients with advanced or unresectable hepatocellular carcinoma (HCC) who have received no prior systemic therapy.
For this indication, competent medicine agencies globally authorize below treatments:
For:
Regimen A: In case that patient weight is ≤ 60 kg, oral, 8 milligrams lenvatinib, once daily.
Regimen B: In case that patient weight is ≥ 60 kg, oral, 12 milligrams lenvatinib, once daily.
The recommended daily dose of lenvatinib is 8 mg once daily for patients with a body weight of <60 kg and 12 mg once daily for patients with a body weight of ≥60 kg. Dose adjustments are based only on toxicities observed and not on body weight changes during treatment. The daily dose is to be modified, as needed, according to the dose/toxicity management plan.
Management of some adverse reactions may require dose interruption, adjustment, or discontinuation of lenvatinib therapy. Mild to moderate adverse reactions (e.g., Grade 1 or 2) generally do not warrant interruption of lenvatinib, unless intolerable to the patient despite optimal management. Details for monitoring, dose adjustment and discontinuation are provided in the following table.
Dose modifications from recommended lenvatinib daily dose in HCC patients:
| Starting Dose | ≥60 kg BW 12 mg | <60 kg BW 8 mg | |
|---|---|---|---|
| Persistent and Intolerable Grade 2 or Grade 3 Toxicitiesa | |||
| Adverse Reaction | Modification | Adjusted Doseb (≥60 kg BW) | Adjusted Doseb (<60 kg BW) |
| First occurrencec | Interrupt until resolved to Grade 0-1 or baselined | 8 mg orally once daily | 4 mg orally once daily |
| Second occurrence (same reaction or new reaction) | Interrupt until resolved to Grade 0-1 or baselined | 4 mg orally once daily | 4 mg orally every other day |
| Third occurrence (same reaction or new reaction) | Interrupt until resolved to Grade 0-1 or baselined | 4 mg orally every other day | Discontinue |
| Life-threatening toxicities (Grade 4): Discontinuee | |||
a Initiate medical management for nausea, vomiting, or diarrhoea prior to interruption or dose reduction.
b Reduce dose in succession based on the previous dose level (12 mg, 8 mg, 4 mg or 4 mg every other day).
c Haematologic toxicity or proteinuria: no dose adjustment required for first occurrence.
d For haematologic toxicity, dosing can restart when resolved to Grade 2; proteinuria, resume when resolves to less than 2 g/24 hours.
e Excluding laboratory abnormalities judged to be nonlife-threatening, which should be managed as Grade 3.
Grades are based on the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE).
Patients ≥75 years, of white race or female sex or those with worse baseline hepatic impairment (Child-Pugh A score of 6 compared to score of 5) appear to have reduced tolerability to lenvatinib.
Lenvatinib should be taken at about the same time each day, with or without food.
Liability Disclaimer : RxReasoner has utilized reasonable care in providing content and services that are accurate, complete and up to date. However, RxReasoner does not accept any responsibility or liability about it. The content and services of RxReasoner are for informational purposes only and they are not intended to be a substitute for the knowledge, expertise, skill, and judgment of physicians, pharmacists, nurses, or other healthcare professionals involved in patient care. RxReasoner offers no medical advice. Users are responsible for the use of the provided content. A shown indication or treatment should not be construed to indicate that the medication is safe, appropriate, or effective in any given patient or under any particular circumstances. The absence of an indication or treatment should not roule out the existence of other appropriate medications. Always seek the advice of a physician or other qualified health provider with any questions you may have regarding a medical condition or medicament. RxReasoner is not liable for any damages allegedly sustained arising out of the use of its content and services.
